Media

MIPS continues to be confident about its leading technology

Nordic Nanovector: Promising results from preclinical studies with a novel CD37-targeted alpha therapy for B-cell tumours presented at TAT11

Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing

Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update

District Court of Delaware rules that Actavis does not infringes with their Suboxone® and Subutex® generics

MIPS AB today publishes the 2018 Annual Report

Strongbridge Biopharma plc Announces Presentation of New Data Analyses from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome

MIPS unable to replicate new WaveCel helmet technology performance claims

Orexo publishes the Annual Report for 2018

MIPS comments communication from Bontrager regarding new technology in some of its helmet models